[HTML] nih.gov

[HTML][HTML] Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway

DP Wu, Y Zhou, LX Hou, XX Zhu, W Yi… - … Journal of Biological …, 2021 - ncbi.nlm.nih.gov
Tamoxifen (TAM) resistance has indicated a significant challenge during endocrine therapy
for hormone-sensitive breast cancer. Thus, it is significant to elucidate the molecular events …
被引用次数：35 相关文章

Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway.

DP Wu, Y Zhou, LX Hou, XX Zhu, W Yi… - … Journal of Biological …, 2021 - europepmc.org
Tamoxifen (TAM) resistance has indicated a significant challenge during endocrine therapy
for hormone-sensitive breast cancer. Thus, it is significant to elucidate the molecular events …

Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway

DP Wu, Y Zhou, LX Hou, XX Zhu… - International …, 2021 - pubmed.ncbi.nlm.nih.gov
Tamoxifen (TAM) resistance has indicated a significant challenge during endocrine therapy
for hormone-sensitive breast cancer. Thus, it is significant to elucidate the molecular events …
[HTML] ijbs.com

[HTML][HTML] Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway

DP Wu, Y Zhou, LX Hou, XX Zhu, W Yi, SM Yang… - International Journal of …, 2021 - ijbs.com
Tamoxifen (TAM) resistance has indicated a significant challenge during endocrine therapy
for hormone-sensitive breast cancer. Thus, it is significant to elucidate the molecular events …
[PDF] semanticscholar.org

[PDF][PDF] Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway

DP Wu, Y Zhou, LX Hou, XX Zhu… - International …, 2021 - pdfs.semanticscholar.org
Tamoxifen (TAM) resistance has indicated a significant challenge during endocrine therapy
for hormone-sensitive breast cancer. Thus, it is significant to elucidate the molecular events …